1,018 results on '"Rowe, Steven M."'
Search Results
152. Synthetic Aminoglycosides Efficiently Suppress Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations and Are Enhanced by Ivacaftor
153. Cystic Fibrosis Transmembrane Conductance Regulator Activation by Roflumilast Contributes to Therapeutic Benefit in Chronic Bronchitis
154. Pharmaceuticals Targeting Nonsense Mutations in Genetic Diseases: Progress in Development
155. Novel Correctors and Potentiators Enhance Translational Readthrough in CFTR Nonsense Mutations
156. Inhaled gene therapy of preclinical muco-obstructive lung diseases by nanoparticles capable of breaching the airway mucus barrier.
157. Changes in Glucose Breath Test in Cystic Fibrosis Patients Treated With 1 Month of Lumacaftor/Ivacaftor.
158. Advancement of magnetomotive micro optical coherence tomography (μOCT) microrheology for probing mucus viscoelastic properties
159. Cigarette Smoke Induces Systemic Defects in Cystic Fibrosis Transmembrane Conductance Regulator Function
160. Airway Remodeling in Ferrets with Cigarette Smoke Induced COPD using µCT Imaging Supplement File
161. Efficacy and Safety of the CFTR Potentiator Icenticaftor (QBW251) in COPD: Results from a Phase 2 Randomized Trial
162. Bioelectric effects of quinine on polarized airway epithelial cells
163. Abstracts from the 23rd Italian congress of Cystic Fibrosis and the 13th National congress of Cystic Fibrosis Italian Society
164. Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10kb C-to-T splicing mutation
165. Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR. A Clinical Trial
166. A Novel G542X CFTR Rat Model of Cystic Fibrosis Is Sensitive to Nonsense Mediated Decay
167. Mechanisms of disease: Cystic fibrosis
168. A simple test could extend cystic-fibrosis treatments to those left behind
169. THE G551D OBSERVATIONAL TRIAL (GOAL): NEW INSIGHTS INTO CFTR MODULATION FROM THE CLINIC: S10.4
170. Understanding the Relationship Between Sweat Chloride and Lung Function in Cystic Fibrosis
171. Comparison of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) and Ciliary Beat Frequency Activation by the CFTR Modulators Genistein, VRT-532, and UCCF-152 in Primary Sinonasal Epithelial Cultures
172. Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in the Lower Airways in COPD
173. Reduced Sodium Transport With Nasal Administration of the Prostasin Inhibitor Camostat in Subjects With Cystic Fibrosis
174. Nasal Potential Difference Measurements to Assess CFTR Ion Channel Activity
175. Ivacaftor restores delayed mucociliary transport caused by Pseudomonas aeruginosa–induced acquired cystic fibrosis transmembrane conductance regulator dysfunction in rabbit nasal epithelia.
176. Clearance of initial mucoid Pseudomonas aeruginosa in patients with cystic fibrosis
177. Progress in cystic fibrosis and the CF Therapeutics Development Network
178. Purification of CFTR for mass spectrometry analysis: identification of palmitoylation and other post-translational modifications
179. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation
180. Colaboradores
181. A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
182. MEASURING CFTR ACTIVITY IN CLINICAL TRIALS: IN VIVO ASSAYS: S14.2
183. COMBINATION OF CORRECTORS AND POTENTIATORS FOR F508DEL CFTR: S15.3
184. Ivacaftor Reverses Airway Mucus Abnormalities in a Rat Model Harboring a Humanized G551D-CFTR
185. G551D mutation impairs PKA-dependent activation of CFTR channel that can be restored by novel GOF mutations
186. Novel Therapy of Bicarbonate, Glutathione, and Ascorbic Acid Improves Cystic Fibrosis Mucus Transport
187. Contribution of Short Chain Fatty Acids to the Growth of Pseudomonas aeruginosa in Rhinosinusitis
188. Fibroblast Growth Factor Receptor 4 Deficiency Mediates Airway Inflammation in the Adult Healthy Lung?
189. Brd4-p300 inhibition downregulates Nox4 and accelerates lung fibrosis resolution in aged mice
190. Airway remodeling in ferrets with cigarette smoke-induced COPD using µCT imaging
191. Haemophilus influenzaepersists in biofilm communities in a smoke-exposed ferret model of COPD
192. CFTR targeted therapies: recent advances in cystic fibrosis and possibilities in other diseases of the airways
193. Human Nasal Epithelial Organoids for Therapeutic Development in Cystic Fibrosis
194. Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications
195. Females with Cystic Fibrosis Demonstrate a Differential Response Profile to Ivacaftor Compared with Males
196. Ataluren/ivacaftor combination therapy: Two N‐of‐1 trials in cystic fibrosis patients with nonsense mutations
197. Disease modification and biomarker development in Parkinson disease
198. Pulmonary artery enlargement is associated with pulmonary hypertension and decreased survival in severe cystic fibrosis: A cohort study
199. Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation
200. The Effects of the Anti-aging Protein Klotho on Mucociliary Clearance
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.